Goldman Sachs’s Palisade Bio PALI Stock Holding History

Goldman Sachs’s Portfolio PALI Stock Details PALI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.48M	Sell	3,578,020 -1,795,931	-33%	-$3.53M	﹤0.01%	3515
2026 Q1	$9.4M	Buy	5,373,951 +4,816,386	+864%	+$8.76M	﹤0.01%	3124
2025 Q4	$1.31M	Buy	+557,565	New	+$1.07M	﹤0.01%	4923
2017 Q1	–	Hold	0	–	-$3K	–	6936
2016 Q4	–	Hold	0	–	–	–	6835
2016 Q3	–	Hold	0	–	–	–	6936
2016 Q2	–	Hold	0	–	–	–	6944
2016 Q1	–	Hold	0	–	–	–	6897
2015 Q4	–	Hold	0	–	–	–	5849
2015 Q3	–	Sell	-1	Closed	-$1.84M	–	5329
2015 Q2	$1.43M	Buy	+1	New	+$2.18M	﹤0.01%	4189
2015 Q1	–	Hold	0	–	–	–	6907
2014 Q4	–	Hold	0	–	–	–	6814
2014 Q3	–	Hold	0	–	–	–	5303
2014 Q2	–	Hold	0	–	–	–	4810
2014 Q1	–	Hold	0	–	–	–	5325

Other funds holding PALI

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

BGI

B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Goldman Sachs's PALI Position: Q2 2026 in Review

Goldman Sachs reduced its Palisade Bio (PALI) stake by 33% in Q2 2026, selling an estimated $3.53M and leaving 3,578,020 shares worth $7.48M. The position accounts for ﹤0.01% of the portfolio, ranked #3515.

Goldman Sachs first reported a position in PALI in Q2 2015 and has held it in 4 quarters since. The position peaked at $9.4M in Q1 2026. 124 funds tracked by Wall St. Rank hold PALI as of Q2 2026.

Goldman Sachs held 3,578,020 shares of Palisade Bio worth $7.48M as of Q2 2026.
Goldman Sachs sold 1,795,931 Palisade Bio shares in Q2 2026, an estimated $3.53M.
Palisade Bio made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #3515 holding.
Goldman Sachs first reported a position in Palisade Bio in Q2 2015 and has held it in 4 quarters since.
Goldman Sachs's Palisade Bio position peaked at $9.4M in Q1 2026.
124 funds tracked by Wall St. Rank held Palisade Bio as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.